Catalyst Event
Pfizer Inc (PFE) · Other
From Akros U.S. Large Cap 500 Protective Allocation Monthly Index (A500PAM)
6/8/2026, 12:00:00 AM
The U.S. FDA approved an expanded indication for Hympavzi (marstacimab-hncq) for treating hemophilia A or B in patients 12 and older with inhibitors, and pediatric patients aged 6 to 11 with or without inhibitors on June 8, 2026, expected. Estimated medium impact due to expanded market reach.
Korean Translation
미국 FDA, 2026년 6월 8일 혈우병 A 또는 B를 앓고 있는 12세 이상 억제인자 보유 환자 및 6-11세 소아 환자 치료를 위해 힘파브지(Hympavzi)의 확대 적응증을 승인할 것으로 예상됨. 시장 확대에 따른 중간 수준의 영향 예상됨.
Related Recent Events
Kinder Morgan Inc. (KMI) · Other
James Holland, Chief Operating Officer, is set to retire, effective September 4, 2026. Ken Grubb, currently VP and Chief Project Officer, will succeed him as COO. The transition was announced on April 22, 2026. Impact is estimated at 1% due to the planned nature of the succession scheduled.
9/4/2026, 12:00:00 AM
HEICO Corp (HEI) · Earnings Release
Q3 2026 earnings release on 2026-08-24 scheduled.
8/24/2026, 12:00:00 AM
Walmart Inc (WMT) · Earnings Release
Q2 FY2027 earnings release scheduled; medium impact from financial updates expected.
8/20/2026, 12:00:00 AM
Target Corp (TGT) · Earnings Release
Q2 2026 earnings release on August 19, 2026, with analysts forecasting an EPS of approximately $2.21-$2.25; low impact estimated as the market typically prices in consensus expectations prior to the release expected.
8/19/2026, 12:00:00 AM
CoreWeave Inc (CRWV) · Earnings Release
Q2 2026 earnings release for August 18, 2026, is of high importance as such releases often cause >10% price impact; event scheduled.
8/18/2026, 12:00:00 AM
Home Depot Inc. (The) (HD) · Earnings Release
Q2 2026 earnings release and conference call on August 18, 2026. Estimated price impact ~5% as earnings releases typically drive significant volatility; scheduled.
8/18/2026, 12:00:00 AM